Advertisement
Advertisement
DWTX
Dogwood Therapeutics, Inc. Common Stock
1.84
USDSponsored
+0.01
+0.55%
Aug 11, 15:59 UTC -4
Closed
After-Market
1.84
0.00
+0.27%
DWTX Earnings Reports
Positive Surprise Ratio
DWTX beat 13 of 20 last estimates.
65%
Next Report
Today
Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.14
Implied change from Q1 26 (Revenue/ EPS)
--
/-6.67%
Implied change from Q2 25 (Revenue/ EPS)
--
/-92.96%
Dogwood Therapeutics, Inc. Common Stock earnings per share and revenue
On May 14, 2026, DWTX reported earnings of -0.15 USD per share (EPS) for Q1 26, beating the estimate of -0.26 USD, resulting in a 42.70% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +6.45% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an decrease of -6.67% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bicara Therapeutics Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.84
Actual
-$0.82
Surprise
+3.18%
Septerna, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.28
Surprise
+33.26%
Autolus Therapeutics plc - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.22
Actual
-$0.15
Surprise
+31.82%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.01
Actual
$0.05
Surprise
+400.00%
LENZ Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.02
Surprise
+6.95%
Codexis, Inc.
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+7.67%
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Legend Biotech Corporation - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.07
Actual
$0.09
Surprise
+17.80%
Mineralys Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.54
Actual
-$2.85
Surprise
-422.26%
Passage Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.69
Actual
-$2.44
Surprise
+9.62%
FAQ
What were Dogwood Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Dogwood Therapeutics, Inc. Common Stock reported EPS of -$0.15, beating estimates by 42.7%, and revenue of $0.00, 0% as expectations.
How did the market react to Dogwood Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 6.45%, changed from $1.86 before the earnings release to $1.98 the day after.
When is Dogwood Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 11, 2026.
What are the forecasts for Dogwood Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Dogwood Therapeutics, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement